<!-- BaNnErBlUrFlE-BoDy-start -->
<!-- Preheader Text : BEGIN -->
<div style="display:none !important;display:none;visibility:hidden;mso-hide:all;font-size:1px;color:#ffffff;line-height:1px;height:0px;max-height:0px;opacity:0;overflow:hidden;">
I have some different concerns that I would like to submit as comments, but I am unsure what “comment category” to select on the submission page. Anyone know? For everyone’s consideration… some additional thoughts I want to convey in my comments</div>
<!-- Preheader Text : END -->
<!-- Email Banner : BEGIN -->
<div style="display:none !important;display:none;visibility:hidden;mso-hide:all;font-size:1px;color:#ffffff;line-height:1px;max-height:0px;opacity:0;overflow:hidden;">ZjQcmQRYFpfptBannerStart</div>
<!--[if ((ie)|(mso))]>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="padding: 16px 0px 16px 0px; direction: ltr" lang="en"><tr><td>
<table border="0" cellspacing="0" cellpadding="0" style="padding: 0px 10px 5px 6px; width: 100%; border-radius:4px; border-top:4px solid #8c8e91;background-color:#CFD3D7;"><tr><td valign="top">
<table align="left" border="0" cellspacing="0" cellpadding="0" style="padding: 4px 8px 4px 8px">
<tr><td style="color:#000000; font-family: 'Arial', sans-serif; font-weight:bold; font-size:14px; direction: ltr">
This Message Is From an External Sender
</td></tr>
<tr><td style="color:#000000; font-weight:normal; font-family: 'Arial', sans-serif; font-size:12px; direction: ltr">
This message came from outside your organization.
</td></tr>
</table>
<![if ie]><br clear="all"><![endif]>
<table align="right" border="0" cellspacing="0" cellpadding="0" style="padding: 4px 0px 4px 0px"><tr>
<td style="direction: ltr"> <a target="_blank" href="https://us-phishalarm-ewt.proofpoint.com/EWT/v1/KGKeukY!vOQfsoZtA8YgRRdxP05k1xrN9_4_qdh7e_ctFD2V0iXAMXRyI9A9F6GHPK4XsEM3mSFo4uTxSt_vNTYN__HcXc3P8TtpkZw2PGBHtytV8yoYTpqL3zuEqe5XwVgQNUzf-tvXHZyIhdgt9BrPiXoknJZxzE_2emK-$" style="mso-padding-alt: 7.5px; padding: 7.5px; border-radius: 2px; border: 1.5px solid #666666; "><strong style="font-weight: normal; color: #000000; text-decoration: none; font-family: 'Arial', sans-serif; font-size:14px; line-height: 40px; "> Report Suspicious </strong></a> </td>
</tr></table>
</td></tr></table>
</td></tr></table>
<![endif]-->
<![if !((ie)|(mso))]>
<div dir="ltr" lang="en" id="pfptBannerytk2uf0" style="all: revert !important; display:block !important; text-align: left !important; margin:16px 0px 16px 0px !important; padding:8px 16px 8px 16px !important; border-radius: 4px !important; min-width: 200px !important; background-color: #CFD3D7 !important; background-color: #CFD3D7; border-top: 4px solid #8c8e91 !important; border-top: 4px solid #8c8e91;">
<div id="pfptBannerytk2uf0" style="all: unset !important; float:left !important; display:block !important; margin: 0px 0px 1px 0px !important; max-width: 600px !important;">
<div id="pfptBannerytk2uf0" style="all: unset !important; display:block !important; visibility: visible !important; background-color: #CFD3D7 !important; color:#000000 !important; color:#000000; font-family: 'Arial', sans-serif !important; font-family: 'Arial', sans-serif; font-weight:bold !important; font-weight:bold; font-size:14px !important; line-height:18px !important; line-height:18px">
This Message Is From an External Sender
</div>
<div id="pfptBannerytk2uf0" style="all: unset !important; display:block !important; visibility: visible !important; background-color: #CFD3D7 !important; color:#000000 !important; color:#000000; font-weight:normal; font-family: 'Arial', sans-serif !important; font-family: 'Arial', sans-serif; font-size:12px !important; line-height:18px !important; line-height:18px; margin-top:2px !important;">
This message came from outside your organization.
</div>
</div>
<div id="pfptBannerytk2uf0" style="all: unset !important; float: right !important; display: block !important; display: block; margin: 0px 0px 0px 16px !important; text-align: right !important; width: fit-content !important;">
<a id="pfptBannerytk2uf0" href="https://us-phishalarm-ewt.proofpoint.com/EWT/v1/KGKeukY!vOQfsoZtA8YgRRdxP05k1xrN9_4_qdh7e_ctFD2V0iXAMXRyI9A9F6GHPK4XsEM3mSFo4uTxSt_vNTYN__HcXc3P8TtpkZw2PGBHtytV8yoYTpqL3zuEqe5XwVgQNUzf-tvXHZyIhdgt9BrPiXoknJZxzE_2emK-$"
style="all: unset !important; display: inline-block !important; text-decoration: none">
<div class="pfptPrimaryButtonytk2uf0" style="display: inline-block !important; display: inline-block; visibility: visible !important; opacity: 1 !important; color: #000000 !important; color: #000000; font-family: 'Arial', sans-serif !important; font-family: 'Arial', sans-serif; font-size: 14px !important; font-weight: normal !important; text-decoration: none !important; border-radius: 2px !important; padding: 7.5px 16px !important; margin: 3px 0 3px 16px !important; white-space: nowrap !important; width: fit-content !important;
border: 1px solid #666666">
Report Suspicious
</div>
</a>
</div>
<div style="clear: both !important; display: block !important; visibility: hidden !important; line-height: 0 !important; font-size: 0.01px !important; height: 0px"> </div>
</div>
<![endif]>
<div style="display:none !important;display:none;visibility:hidden;mso-hide:all;font-size:1px;color:#ffffff;line-height:1px;max-height:0px;opacity:0;overflow:hidden;">ZjQcmQRYFpfptBannerEnd</div>
<!-- Email Banner : END -->
<!-- BaNnErBlUrFlE-BoDy-end -->
<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head><!-- BaNnErBlUrFlE-HeAdEr-start -->
<style>
#pfptBannerytk2uf0 { all: revert !important; display: block !important;
visibility: visible !important; opacity: 1 !important;
background-color: #CFD3D7 !important;
max-width: none !important; max-height: none !important }
.pfptPrimaryButtonytk2uf0:hover, .pfptPrimaryButtonytk2uf0:focus {
background-color: #adb0b4 !important; }
.pfptPrimaryButtonytk2uf0:active {
background-color: #8c8e91 !important; }
html:root, html:root>body { all: revert !important; display: block !important;
visibility: visible !important; opacity: 1 !important; }
</style>
<!-- BaNnErBlUrFlE-HeAdEr-end -->
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Aptos;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
font-size:12.0pt;
font-family:"Aptos",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
{mso-style-priority:34;
margin-top:0in;
margin-right:0in;
margin-bottom:0in;
margin-left:.5in;
font-size:12.0pt;
font-family:"Aptos",sans-serif;}
p.xmsonormal, li.xmsonormal, div.xmsonormal
{mso-style-name:x_msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:12.0pt;
font-family:"Aptos",sans-serif;}
p.xelementtoproof, li.xelementtoproof, div.xelementtoproof
{mso-style-name:x_elementtoproof;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:12.0pt;
font-family:"Aptos",sans-serif;}
span.EmailStyle21
{mso-style-type:personal-reply;
font-family:"Aptos",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;
mso-ligatures:none;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:427966412;
mso-list-type:hybrid;
mso-list-template-ids:-490843316 1106258240 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:-;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Aptos",sans-serif;
mso-fareast-font-family:Aptos;
mso-bidi-font-family:"Times New Roman";}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:"Courier New";}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="blue" vlink="purple" style="word-wrap:break-word">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:11.0pt">I have some different concerns that I would like to submit as comments, but I am unsure what “comment category” to select on the submission page. Anyone know?<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">For everyone’s consideration… some additional thoughts I want to convey in my comments include the following:<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l0 level1 lfo1"><span style="font-size:11.0pt">Size Adjusted Dose (SAD) uses DLP as an input, and in turn is based on CTDI. If CMS mandates this, we will be hardcoding a concept that is already questionable
for cone-beam and wide beam CT. This will be a bigger problem with time.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l0 level1 lfo1"><span style="font-size:11.0pt">Facilities already have a reason to want to produce quality images. We really don’t need an overly simplistic metric to motivate clinics. The idea that
it might prevent a race-to-the-bottom for dose has some merit. But who is to say that facilities don’t simply report based on a recon that suppresses high spatial frequencies with radiologists reading different recons?<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l0 level1 lfo1"><span style="font-size:11.0pt">It might make sense to have voluntary reporting of just dose metrics beginning in 2027 with facilities getting to pick either SSDE or SAD. At a later
date (e.g. 2030 and on) reporting using any AAPM or ACR approved dose metric applicable to the specific technology could be considered.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<div>
<p class="MsoNormal"><span style="font-size:11.0pt;mso-ligatures:standardcontextual">Scott Winter<o:p></o:p></span></p>
</div>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<div>
<div style="border:none;border-top:solid #E1E1E1 1.0pt;padding:3.0pt 0in 0in 0in">
<p class="MsoNormal"><b><span style="font-size:11.0pt;font-family:"Calibri",sans-serif">From:</span></b><span style="font-size:11.0pt;font-family:"Calibri",sans-serif"> Intl_dxmedphys_wd_osu_list <intl_dxmedphys_wd_osu_list-bounces@lists.osu.edu>
<b>On Behalf Of </b>Adam Springer via Intl_dxmedphys_wd_osu_list<br>
<b>Sent:</b> Wednesday, September 10, 2025 9:17 PM<br>
<b>To:</b> kenharper14 via Intl_dxmedphys_wd_osu_list <intl_dxmedphys_wd_osu_list@lists.osu.edu><br>
<b>Subject:</b> [Non-DoD Source] [Intl_DxMedPhys] Fwd: [AMRSO] FW: Urgent help needed on the comment to the new CMS proposition<o:p></o:p></span></p>
</div>
</div>
<p class="MsoNormal"><o:p> </o:p></p>
<div>
<div>
<p class="MsoNormal" style="mso-line-height-alt:.75pt"><span style="font-size:1.0pt;color:white">I saw this post on the AMRSO list but I don’t recall it being discussed on this list. I figure many will be interested. -Adam Begin forwarded message:
</span><span style="font-size:1.0pt;font-family:"Tahoma",sans-serif;color:white"></span><span style="font-size:1.0pt;color:white"> Hello All – just a reminder about the comment period deadline for the CMS proposed rule<o:p></o:p></span></p>
</div>
<div>
<p class="MsoNormal">I saw this post on the AMRSO list but I don’t recall it being discussed on this list. I figure many will be interested. <o:p></o:p></p>
</div>
<div>
<p class="MsoNormal"><o:p> </o:p></p>
</div>
<div>
<p class="MsoNormal">-Adam<br>
<br>
<br>
Begin forwarded message:<br>
<span style="font-family:"Tahoma",sans-serif"></span><o:p></o:p></p>
</div>
<blockquote style="margin-top:5.0pt;margin-bottom:5.0pt">
<div>
<div>
<p class="xmsonormal"><span style="font-size:11.0pt">Hello All – just a reminder about the comment period deadline for the CMS proposed rule change on CT dose reporting. All of this information was compiled and provided by a medical physicist colleague. Comments
from individuals who are technically qualified will carry a lot of weight. </span>
<o:p></o:p></p>
<p class="xmsonormal"><span style="font-size:11.0pt"> </span><o:p></o:p></p>
<p class="xmsonormal"><span style="font-size:11.0pt">-Tara</span><o:p></o:p></p>
<p class="xmsonormal"><span style="font-size:11.0pt"> </span><o:p></o:p></p>
<p class="xmsonormal"> <o:p></o:p></p>
<div>
<p class="xmsonormal"><span style="font-size:11.0pt;color:black">Dear Colleagues, </span><o:p></o:p></p>
</div>
<div>
<p class="xmsonormal"><span style="font-size:11.0pt;color:black"> </span><o:p></o:p></p>
</div>
<div>
<p class="xmsonormal"><span style="font-size:11.0pt;color:black">We would like to have your attention and help with a critical CMS proposition which is currently open for public comment until
<b>Sep 15th</b>. Please see the detailed instruction in the attached documents about the fundamentally flawed measure, which was proposed by a for-profit company and opposed by all major professional societies including RSNA, ACR, AAPM, ASRT and HPS. </span><o:p></o:p></p>
</div>
<div>
<p class="xmsonormal"><span style="font-size:11.0pt;color:black"> </span><o:p></o:p></p>
</div>
<div>
<p class="xmsonormal"><span style="font-size:11.0pt;color:black">The current proposition to be commented on is to set the data reporting for this measure to be
<b>Permanently Voluntary. </b> Therefore, we are strongly in support of this proposition, while the for-profit company is also carrying an overwhelming campaign over social media by using disguising weblinks such "ucsf.us" instead of "uscf.edu".</span><o:p></o:p></p>
</div>
<div>
<p class="xmsonormal"><span style="font-size:11.0pt;color:black"> </span><o:p></o:p></p>
</div>
<div>
<p class="xmsonormal"><span style="font-family:"Calibri",sans-serif;color:black">If you are not familiar with this measure (and the current proposition to make it optional), please refer to the sample texts either in this email below or in the attached sample
letter.</span><o:p></o:p></p>
</div>
<div>
<p class="xmsonormal"><span style="font-family:"Calibri",sans-serif;color:black"> </span><o:p></o:p></p>
</div>
<p class="xelementtoproof"><span style="font-size:11.0pt;color:black">To save everyone’s time, one way is to provide some simple versions of comments (we include several examples below in this email and also in the attached instruction document). Anyone can
directly copy/paste, and submit quickly on the website: </span><u><span style="color:black"><a href="https://urldefense.com/v3/__https:/secure-web.cisco.com/1hSy6k9zrdAPTLR1oDl61VKQAtYRsfpmkl8u3zplpojnwSylMTEZWltisG-bHkqXATG1Y22TIvf645q8MDOnHBkMtXKMLgYNQzONvZfs3RWf300cPRjCR7TG2ad239owN7g_dknEYs9Dl6u2SFTfX0ZKWfiTr3-zTZksKVCn88xjXB5BlD-h1q7sqKJR657BxP1gEQn9QQkvXQNDAcxVryCVCjSvdcTEG8V90xH46-LZQ2PeaD-S6oKV4jgDehEnL_xea1R2CXrms2WYzKRpMZl4bFkRwRtYbEW9sQ8MkPICVh78GwOkL6K2P9rq3xMIU/https*3A*2F*2Fwww.regulations.gov*2Fcommenton*2FCMS-2025-0306-0002__;JSUlJSU!!KGKeukY!0hWFh0hvSnArkmV9Q9QAzzhqk1PsEnPjbi74o_jzwcOuvkiordlZ2_jsAWqsffwN3RV8G_K-_WB6aw3sxwCNPf5eUCvMrfq-6OagYw$"><span style="color:black">https://www.regulations.</span></a></span></u><span style="color:black"><a href="https://urldefense.com/v3/__https:/secure-web.cisco.com/1hSy6k9zrdAPTLR1oDl61VKQAtYRsfpmkl8u3zplpojnwSylMTEZWltisG-bHkqXATG1Y22TIvf645q8MDOnHBkMtXKMLgYNQzONvZfs3RWf300cPRjCR7TG2ad239owN7g_dknEYs9Dl6u2SFTfX0ZKWfiTr3-zTZksKVCn88xjXB5BlD-h1q7sqKJR657BxP1gEQn9QQkvXQNDAcxVryCVCjSvdcTEG8V90xH46-LZQ2PeaD-S6oKV4jgDehEnL_xea1R2CXrms2WYzKRpMZl4bFkRwRtYbEW9sQ8MkPICVh78GwOkL6K2P9rq3xMIU/https*3A*2F*2Fwww.regulations.gov*2Fcommenton*2FCMS-2025-0306-0002__;JSUlJSU!!KGKeukY!0hWFh0hvSnArkmV9Q9QAzzhqk1PsEnPjbi74o_jzwcOuvkiordlZ2_jsAWqsffwN3RV8G_K-_WB6aw3sxwCNPf5eUCvMrfq-6OagYw$"><span style="color:black;text-decoration:none">g</span></a><u><a href="https://urldefense.com/v3/__https:/secure-web.cisco.com/1hSy6k9zrdAPTLR1oDl61VKQAtYRsfpmkl8u3zplpojnwSylMTEZWltisG-bHkqXATG1Y22TIvf645q8MDOnHBkMtXKMLgYNQzONvZfs3RWf300cPRjCR7TG2ad239owN7g_dknEYs9Dl6u2SFTfX0ZKWfiTr3-zTZksKVCn88xjXB5BlD-h1q7sqKJR657BxP1gEQn9QQkvXQNDAcxVryCVCjSvdcTEG8V90xH46-LZQ2PeaD-S6oKV4jgDehEnL_xea1R2CXrms2WYzKRpMZl4bFkRwRtYbEW9sQ8MkPICVh78GwOkL6K2P9rq3xMIU/https*3A*2F*2Fwww.regulations.gov*2Fcommenton*2FCMS-2025-0306-0002__;JSUlJSU!!KGKeukY!0hWFh0hvSnArkmV9Q9QAzzhqk1PsEnPjbi74o_jzwcOuvkiordlZ2_jsAWqsffwN3RV8G_K-_WB6aw3sxwCNPf5eUCvMrfq-6OagYw$"><span style="color:black">ov/commenton/CMS-2025-0306-0002</span></a></u>. </span><o:p></o:p></p>
<p class="xelementtoproof"> <o:p></o:p></p>
<p class="xelementtoproof"><span style="font-size:11.0pt;color:black">The submission itself
<b>only took 1 minute. We encourage everyone to submit individually, either from these simple options or upload a more formal letter using the letter template attached. </b></span><o:p></o:p></p>
<p><span style="font-size:11.0pt;color:black"> </span><o:p></o:p></p>
<p class="xelementtoproof"><b><span style="font-size:11.0pt;color:black">Simple Version 1: </span></b><o:p></o:p></p>
<p><span style="font-size:11.0pt;color:black">I am writing to comment on the proposed rules (<b>CMS-1834-P</b>) regarding the Hospital Outpatient Quality Reporting (OQR) Program, specifically on the proposed change to “Excessive Radiation Dose or Inadequate
Image Quality for Diagnostic Computed Tomography (CT) in Adults” (CMS eCQM ID: CMS1074v1). I strongly support CMS’s proposal to make this quality measure voluntary in 2027 and beyond. The two major metrics in the eCQM, Calculated CT Global Noise and Calculated
CT Size-Adjusted Dose, are fundamentally flawed. They do not reflect how radiologists assess image quality or how physicists measure and calculate radiation dose. They are inconsistent with some of the internationally recognized standards such as Size Specific
Dose Estimate (SSDE). Enforcing fixed limits creates an untenable situation for some patient types that will lead to inferior diagnostic information and missed or incorrect diagnoses. Making the rule voluntary in 2027 and beyond will give time to professional
organizations and CT imaging community to determine more valid metrics that truly monitor diagnostic quality and patient outcomes. </span><o:p></o:p></p>
<p><span style="font-size:11.0pt;color:black"> </span><o:p></o:p></p>
<p><b><span style="font-size:11.0pt;color:black">Simple Version 2:</span></b><o:p></o:p></p>
<p><span style="font-size:11.0pt;color:black">This comment is regarding the proposed rules (<b>CMS-1834-P</b>), particularly on the proposed changes to the eCQM titled “Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography
(CT) in Adults” (CMS eCQM ID: CMS1074v1). I strongly support the proposal to make this rule voluntary at 2027 and beyond. The measure’s core metrics, “Calculated CT Global Noise” and “Calculated CT Size-Adjusted Dose”, have not received broad and strict validation
in the clinical and scientific community. This measure relies on use of a software tool that has been developed and is to be provided by a for-profit company, and that same company is the proponent of the measure. This is an inherent conflict of interest.
Before the rule becomes mandatory, CMS should require independent studies, peer-reviewed evidence, and multiple implementation options. Making it voluntary at 2027 and beyond is the right thing to do.</span><o:p></o:p></p>
<p><span style="font-size:11.0pt;color:black"> </span><o:p></o:p></p>
<p><b><span style="font-size:11.0pt;color:black">Simple Version 3:</span></b><o:p></o:p></p>
<p><span style="font-size:11.0pt;color:black">This comment is about <b>CMS-1834-P</b> and the recently proposed changes to eCQM CMS1074v1: Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography (CT) in Adults. I strongly endorse
the proposed change to make it voluntary in 2027 and beyond. The implementation in the original rule depends on ALARA Imaging, which is a new (2020), for-profit startup company with no track record of having previously performed any project on imaging, let
alone a project of such wide scope, scientifically or technically. Sufficient time has not been allowed for testing with this company or for alternative companies to develop products that would allow a practice to comply with this measure. A voluntary period
will allow careful further validation studies, fair competition among different commercial or academic tools, and simpler workflow before the rule becomes mandatory.</span><o:p></o:p></p>
<p class="xelementtoproof"><span style="font-size:11.0pt;color:black"> </span><o:p></o:p></p>
<p class="xelementtoproof" style="margin-bottom:8.0pt"><b><span style="font-size:11.0pt;color:black">Simple Version 4:</span></b><o:p></o:p></p>
<div style="margin-bottom:8.0pt">
<p class="xmsonormal"><span style="font-size:11.0pt;color:black">I am writing to comment on
<b>CMS-1834-P</b> and the recently proposed changes to eCQM CMS1074v1: Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography (CT) in Adults. I strongly endorse the proposed change to make it voluntary in 2027 and beyond. Since
the mandatory requirement imposes unnecessary regulatory burden and increase operational costs without corresponding improvements in patient care or system efficiency.</span><o:p></o:p></p>
</div>
<div style="margin-bottom:8.0pt">
<p class="xmsonormal"><span style="font-size:11.0pt;color:black">While the goal of improving transparency and quality in hospital outpatient and ambulatory surgical center payments is commendable, some provisions appear overly complex and administratively burdensome.
These requirements could divert critical resources away from direct patient care and create additional compliance challenges for healthcare providers.</span><o:p></o:p></p>
</div>
<div style="margin-bottom:8.0pt">
<p class="xmsonormal"><span style="font-size:11.0pt;color:black">I urge regulators to carefully consider the cost-benefit balance of these requirements and explore opportunities to streamline reporting and documentation processes. Minimizing unnecessary regulatory
burden is essential to fostering innovation, reducing administrative overhead, and ultimately improving healthcare delivery.</span><o:p></o:p></p>
</div>
<div>
<p class="xmsonormal"><span style="font-size:11.0pt;color:black"> </span><o:p></o:p></p>
</div>
</div>
<p class="xmsonormal">The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Mass General Brigham Compliance
HelpLine at <a href="https://urldefense.com/v3/__https:/www.massgeneralbrigham.org/complianceline__;!!KGKeukY!0hWFh0hvSnArkmV9Q9QAzzhqk1PsEnPjbi74o_jzwcOuvkiordlZ2_jsAWqsffwN3RV8G_K-_WB6aw3sxwCNPf5eUCvMrfr7wcLjCA$">
https://www.massgeneralbrigham.org/complianceline</a> .<o:p></o:p></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="xmsonormal">Please note that this e-mail is not secure (encrypted). If you do not wish to continue communication over unencrypted e-mail, please notify the sender of this message immediately. Continuing to send or respond to e-mail after receiving
this message means you understand and accept this risk and wish to continue to communicate over unencrypted e-mail.
<o:p></o:p></p>
</div>
</blockquote>
</div>
</div>
</body>
</html>